ACCISS Study Report | Biosimilar Insulin Regulatory Profile

ACCISS Study Report | 6 April 2017 –  Report | Fact Sheet

The Biosimilar Insulin Regulatory Profile discusses the regulatory pathways and challenges faced by companies seeking marketing authorisation for insulin biosimilars, particularly in highly-regulated markets such as the European Union (EU) and the United States (US).  It also includes a case study of two manufacturers who sought marketing authorisation from the European Medicines Agency (EMA) for insulin products.

2016 Annual Report & Financial Statements

2016 Annual Report & Financial Statements | 5 April, 2017 | Download PDF

About Health Action International
Health Action International (HAI) is the only independent, non-profit, civil society organisation entirely dedicated to improving access to medicines and the rational use of medicines. As a
Dutch-registered ‘stichting’ (foundation) established in 1981,

Report | The Sun Shines on Europe: transparency of financial relationships in the healthcare sector

Report | 29 March 2017 | Download PDF

Pharmaceutical companies employ a wide range of promotional activities to increase medicines prescription rates and maximise their profit. Some of the strategies companies use to influence healthcare professionals include the provision of hospitality to attend events, free meals and gift-giving. At the same time,

ACCISS Study Report | Access to Insulin: Current Challenges and Constraints

ACCISS Study Report | 23 March 2017 | Download PDF

Executive Summary

The Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS) Study has completed its first phase of work, which aimed to gain an overall understanding of the insulin market through different profiles. These included profiles on the insulin market,

Position Statement: TACD Positive Consumer Agenda – New Rules for the Global Economy

Position Statement | 20 March, 2017 | Download Link

Trade agreements — their scope, transparency and legitimacy — must now be reimagined. This paper outlines a consensus position of the Transatlantic Consumer Dialogue (TACD), a coalition of more than 75 European and US-based consumer organizations. It is intended to be an initial vision on how trade agreements should be limited to trade matters,

Media Release: Health Action International start een publiekscampagne tegen stijgende medicijnprijzen

Media Release | 7 March 2017 | Download PDF

AMSTERDAM—Vandaag lanceert Health Action International een campagne waarin zij verkiezingskandidaten oproept om een einde te maken aan stijgende medicijnprijzen in Nederland. De kosten van de duurste geneesmiddelen zijn inmiddels opgelopen tot €1,7 miljard per jaar.

“De prijzen rijzen de pan uit.

Media Release: Soaring Medicine Prices the Target Of New Public Campaign Ahead Of 15 March Election

Media Release | 7 March 2017 | Download PDF

AMSTERDAM—A campaign launched by Health Action International today calls on political candidates running in the Dutch national election to commit to putting an end to soaring medicine prices in The Netherlands, where expenditure on the highest-priced pharmaceuticals has reached €1.7 billion per year.

Media Statement: European Parliament Hits Target in Recommendations for Improving Access to Medicines

Media Statement | 3 March 2017 | Download PDF

AMSTERDAM—Health Action International commends the European Parliament for its Report on European Union (EU) Options for Improving Access to Medicines, the timing of which is crucial given the increasing inability for healthcare systems to provide access to high-priced medicines.

Conference Report: Clinical Drug Trials

Conference Report | 7 February 2017 | Download PDF

Clinical trials are at the core of fundamental decisions that are taken on a regular basis in the field of public health by regulatory authorities – such as marketing authorisation procedures.

For pharmaceutical companies, clinical trials are thus at the heart of fierce commercial interests as a marketing approval can represent huge money for its producer,